Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Affinivax to Present at the 40th Annual J.P. Morgan Healthcare Conference


Affinivax, Inc. ("Affinivax"), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPStm (Multiple Antigen Presenting System) platform, today announced that Steven Brugger, president and CEO of Affinivax, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:30 a.m. ET. The virtual conference will be held from January 10-13, 2022.

About Affinivax, Inc.

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPStm technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children's Hospital. For more information, visit www.affinivax.com.


These press releases may also interest you

at 22:03
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

at 20:35
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
Media Advisory - Minister Saks in Winnipeg to highlight Budget 2024: Fairness for Every Generation investments to boost research funding in Canada
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting A Solution Panel Aims to Find Solutions for the Veteran Suicide Crisis with National Thought Leaders Tulsi Gabbard, Tim Kennedy, and Dan Hollaway
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

at 18:15
Equality Health Foundation Expands Reach to Virginia and Louisiana
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...

More news about Health...


News published on and distributed by: